Insider Trading Alert - ANAC, N And PRAA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 24, 2014, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $820.00 to $144,690,560.42.

Highlighted Stocks Traded by Insiders:

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Parker Geoffrey M. who is Senior Vice President and CFO at Anacor Pharmaceuticals bought 5,000 shares at $20.11 on March 24, 2014. Following this transaction, the Senior Vice President and CFO owned 163,410 shares meaning that the stake was reduced by 3.16% with the 5,000-share transaction.

Maples Kirk R who is SVP, Program Management at Anacor Pharmaceuticals sold 3,000 shares at $22.39 on March 24, 2014. Following this transaction, the SVP, Program Management owned 4,620 shares meaning that the stake was reduced by 39.37% with the 3,000-share transaction.

The shares most recently traded at $20.02, down $2.37, or 11.83% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 86,000
  • 24-Week # shares sold: 89,000

The average volume for Anacor Pharmaceuticals has been 483,800 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $887.4 million and is part of the health care sector and drugs industry. Shares are up 19.07% year-to-date as of the close of trading on Monday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has a P/E ratio of 10.7. Currently there are 2 analysts that rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Lack of Catalysts Keeps Analysts Away From Pfizer

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Allergan's Dealmaking Continues With Vitae Takeout

Will Pfizer Book Another Healthy Quarter?

Ardelyx Has Big Potential

Ardelyx Has Big Potential